Adaptimmune Therapeutics PLC at Citi Immuno-Oncology Summit (Virtual) Transcript
Welcome, everyone, to day 2 of Citi's Immuno-Oncology Summit. I am Yigal Nochomovitz, one of the biotech analysts here at Citi. Most of you know me. (Operator Instructions)
So with that, it's my great pleasure to welcome the management team from Adaptimmune. We have Gavin Wood, CFO; Elliot Norry, CMO; and Juli Miller, VP IR. So welcome, everyone. Thank you so much for taking the time. Maybe just to start out, Gavin, if you would like to summarize the overall strategy for Adaptimmune for those listeners that are less familiar with the story?
It's Ad Rawcliffe, CEO. I'll just touch on areas of focus for this year. Adaptimmune is a late-stage, integrated cell therapy company, focused on the TCR T-cell space for solid tumors. We have a strategy that we laid out a couple of years ago. It's unashamedly a product-oriented strategy as we're leading in late-stage clinical trials and approaching
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
